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Abstract: Endo-, phyto- and synthetic cannabinoids have been proposed as promising anti-cancer
agents able to impair cancer cells’ behavior without affecting their non-transformed counterparts.
However, cancer outcome depends not only on cancer cells’ activity, but also on the stromal
cells, which coevolve with cancer cells to sustain tumor progression. Here, we show for the first
time that cannabinoid treatment impairs the activation and the reactivity of cancer-associated
fibroblasts (CAFs), the most represented stromal component of prostate tumor microenvironment.
Using prostate cancer-derived CAFs, we demonstrated that WIN 55-212.2 mesylate, a synthetic
full agonist of cannabinoid receptors (CBs) 1 and 2, downregulates α-smooth muscle actin and
matrix metalloprotease-2 expression, and it inhibits CAF migration, essential features to ensure
the activated and reactive CAF phenotype. Furthermore, by impairing stromal reactivity, WIN
55-212.2 mesylate also negatively affects CAF-mediated cancer cells’ invasiveness. Using selective
antagonists of CBs, we proved that CAFs response to WIN 55-212.2 mesylate is mainly mediated by
CB2. Finally, we suggest that endocannabinoids self-sustain both prostate tumor cells migration and
CAFs phenotype by an autocrine loop. Overall, our data strongly support the use of cannabinoids as
anti-tumor agents in prostate cancer, since they are able to simultaneously strike both cancer and
stromal cells.
Keywords: WIN 55-212.2 mesylate; cannabidiol; endocannabinoids; cancer-associated fibroblasts;
prostate cancer
1. Introduction
Cannabinoids are bioactive lipids able to interact with specific cell-surface cannabinoid receptors
(CBs). They can be divided into three main classes: endocannabinoids (endogenous ligands),
phytocannabinoids (derived from Cannabis Sativa), and synthetic cannabinoids. In the last few
decades, growing evidence has reported their ability to impair cancer progression both in vitro
and in xenograft models of human cancers. The anti-tumorigenic activities include: (i) inhibition
of cancer cells’ proliferation and migration, (ii) induction of cancer cell death, (iii) impairment of
neoangiogenesis, and (iv) modulation of anti-tumor immune response [1–3]. ∆-9-tetrahydrocannabinol
(THC) and cannabidiol (CBD) are the two best-characterized active components contained in marijuana.
THC binds with high affinity both CB1 and CB2, while CBD, which lacks psychotropic activity, mainly
interacts with vanilloid receptor 1 (TRPV1). Of interest, CB1 and CB2 were found up-regulated in
malignant tissues compared to their non-transformed counterparts and a correlation between high
expression and poor prognosis has been proven for different human tumors [4].
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Cannabinoids have been shown to be promising anticancer agents in prostate cancer treatment [5].
In prostate cancer patients, high expression of CB1 has been associated with a worse prognosis [6,7], and
several authors reported CB1-mediated anti-proliferative and anti-invasive effects of cannabinoids in
prostate cancer cells [8–12]. Furthermore, it has been recently demonstrated that CB2 also controls tumor
cells proliferation, migration, and invasion in both prostate cancer cell lines and in vivo models [13].
To date, it is widely accepted that cancer outcome does not only depend on the behavior of cancer
cells, but also on the tumor microenvironment (TME) that coevolves with cancer cells, sustaining the
enhancement of tumor malignancy. We previously demonstrated that cancer-associated fibroblasts
(CAFs), the most represented stromal cells in the prostate TME, play an intriguing role during all
stages of disease progression, including metastasis [14–20]. Herein, we show a selective action of WIN
55-212.2 mesylate, a synthetic cannabinoid with affinity for CB1 and CB2 higher than THC, on prostate
cancer cell lines without affecting healthy counterpart. Furthermore, we demonstrated for the first
time that patient-derived prostate CAFs upregulate CBs expression compared to normal fibroblasts
(HPFs). WIN 55-212.2 mesylate strongly impaired CAFs’ activation and CAFs-induced tumor invasion.
By using selective antagonists of CB1 and CB2, we proved that WIN 55-212.2 mesylate operated mainly
through CB2. Finally, we demonstrated that migration of androgen-independent prostate cancer cells
(PC-3 and DU-145) and CAFs phenotype could be regulated by an autocrine self-sustaining loop
of endocannabinoids.
Overall, these data support the use of cannabinoids as promising anti-cancer drugs in prostate
cancer patients, since they are able to simultaneously strike cancer and stromal cells.
2. Results
2.1. WIN 55-212.2 Mesylate Selectively Impairs Prostate Cancer Cells Survival
The best-characterized anti-tumoral activities of cannabinoids are their ability to induce cancer cell
death by apoptosis and to inhibit cancer cell proliferation [3,21,22]. In keeping with those, we evaluated
the anti-proliferative effects of WIN 55-212.2 mesylate and CBD in both androgen-sensitive (LNCaP)
and insensitive (PC-3 and DU-145) prostate cancer cells. As a control, we used healthy prostate
epithelial cells (PNT-1). Tumor and control cells were treated for 24 h with concentrations of WIN
55-212.2 mesylate and CBD ranging from 0.5 to 100 µM, and then cell viability was analyzed by crystal
violet staining (Figure 1a). Our results show that WIN 55-212.2 mesylate at concentrations ≥ 5 µM
is a selective anti-tumor compound, able to kill tumor cells without affecting their non-transformed
counterparts. Interestingly, CBD 5 µM reduces almost 50% of tumor cells’ viability, while PNT-1
survival decreases only 20%. Then, we evaluated CBs’ and TRPV1’s expression in our cell models
(Figure 1b). Western blot analysis revealed that the normal prostate epithelial cells express similar levels
of CB1 and TRPV1, while exhibiting lower levels of CB2. All cannabinoid receptors strongly increase
in tumor cells with respect to PNT-1. Interestingly, CB1 expression and CB2 expression are both higher
in LNCaP compared to PC-3 and DU-145 cells, while TRPV1 is modulated in an opposite manner.
Figure 1. Cont.
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Figure 1. WIN 55-212.2 mesylate impacts on prostate cancer cell survival without affecting healthy
prostate epithelial cells (a) Normal prostate epithelial cells (PNT-1), androgen-sensitive (LNCaP), and
insensitive (PC-3 and DU-145) prostate cancer cells were incubated with increasing concentrations
of WIN 55-22.2 mesylate and CBD for 24 h. Cell survival measurements by means of data obtained
by crystal violet staining are shown (n = 3). p-Values were determined by Student’s t test. * p < 0.05,
** p < 0.01, *** p < 0.001 WIN versus control (Untr); # p < 0.05, ### p < 0.001 CBD versus Untr.
(b) Representative immunoblot of CB1, CB2 and TRPV1 expressions in PNT-1 and prostate cancer cell
lines (c) Quantitative results of western blot analysis. Relative expressions were normalized respect
to GAPDH. Each dot represents a biological replicate. Data express means ± SEMs. p-values were
calculated by one-way ANOVA followed by Bonferroni’s multiple comparison test. * p < 0.05, ** p <
0.01, *** p < 0.001 versus PNT-1; # p < 0.05, ## p < 0.01 versus LNCaP; § p < 0.05 versus PC-3.
2.2. CAFs Derived from Aggressive Prostate Cancer Bearing Patients Upregulate CB1 and CB2 Compared to
Normal Fibroblasts
The expression of CBs and TRPV1 has been evaluated in primary patient-derived fibroblasts.
CAFs were isolated from aggressive prostate cancer bearing patients (Gleason score 4 + 5, 4 + 4,
grade ≤ pT3), while normal fibroblasts were obtained from the adjacent non-neoplastic area. Western
blot analysis indicates that CB1 and CB2 are up-regulated in CAFs compared to HPFs, while TRPV1
is weakly expressed in both cell types, without significant differences between them (Figure 2a,b).
To investigate the regulation of CBs during activation of normal fibroblasts in the CAFs phenotype,
HPFs were stimulated for 48 h with three different inflammatory cytokines: transforming growth factor
(TGF)-β, interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Indeed, prostate cancer cells release
high concentrations of TGF-β and IL-6 inside the TME, which play a mandatory role in the activation
of resident fibroblasts into CAFs [14,23–25]. Concerning TNF-α, it has been recently proven that it is
able to modulate the CB2 expression in human T cells and PBMCs [26]. Our results show that all the
tested cytokines are able to induce CBs expression, with significant increase in CB2 levels (Figure 2c,d).
In keeping with the high abundance of IL-6 and TGF-β in prostate cancer cells’ secretome, conditioned
media from DU-145 cells also upregulate both CB1 and CB2 expression in treated HPFs (Figure 2e).
To confirm the role of tumor-secreted IL-6 and TGF-β in modulating CBs expression, HPFs were
treated with conditioned media from DU-145 cells in the presence of and without blocking antibodies
for IL-6 (α-IL-6) and a selective inhibitor of TGF-β receptor 1 (A8301). We previously proved that
α-IL-6 is functional at the concentration of 5 µg/mL [27], while the dose 1 µM of A8301 was established
by evaluating activation of SMAD2/3 in a dose-response experiment (Figure S1a). As expected, CB2
expression is regulated by both IL-6 and TGF-β pathways (Figure 2e).
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Figure 2. Prostate cancer patient-derived CAFs upregulate CB1 and CB2 receptors in response to
inflammatory cytokines. (a) Representative immunoblot of CBs, TRPV1, and α-SMA expression in
normal fibroblasts (HPFs) and cancer-associated fibroblasts (CAFs) isolated from two different explants
(HPF1/HPF2; CAF1/CAF2). (b) Quantitative results of western blot analysis performed in HPFs (n = 3)
and CAFS (n = 4). Relative expressions were normalized respect to GAPDH. Each dot represents
a biological replicate (n = 6 for CB1, n = 7 for CB2, n = 4 for TRPV1). Data represent means ± SEMs.
p-values were calculated by Student’s t test. * p < 0.05, ** p < 0.01 versus HPFs. (c) Expression of CBs in
two different primary HPFs (HPF1/HPF2) stimulated for 48 h with TGF-β 10 ng/mL, IL-6 100 ng/mL,
and TNF-α 25 ng/mL. Cells maintained in serum-deprived medium have been used as control (Untr).
(d) Quantitative results of western blot analysis performed twice on two different patient-derived
HPFs. Data represent means ± SEMs. One-way ANOVA, Dunnet’s corrected. * p < 0.05 versus Untr.
(e) Representative immunoblot of CBs expression on HPFs treated for 48 h with the conditioned media
(CM) from DU-145 cells, in presence or not of TGF-β receptor inhibitor (A8301, 1 µM) and neutralizing
antibodies for IL-6 (α-IL-6, 5 µg/mL). Cells were pre-treated with inhibitors for 1 h, and then the CM
from tumor cells was added. Cells maintained in serum-deprived medium have been used as control
(Untr). (f) Quantitative results of western blot analysis performed twice on HPFs obtained from two
different explants. Data represent means ± SEMs. One-way ANOVA, Dunnet’s corrected. ** p < 0.01
versus Untr; # p < 0.05 versus CM-DU-145.
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2.3. WIN 55-212.2 Mesylate Impacts on CAFs Phenotype and Impairs TGF-β-Induced Activation in Normal
Fibroblasts via CB2 Receptor
In line with differential expression of CBs between HPFs and CAFs, we tested if the treatment with
WIN 55-212.2 mesylate and CBD could differentially affect HPFs and CAFs survival. We assessed the
survival rate following 24 h of treatment with cannabinoids, with concentrations ranging from 0.5 µM
to 100 µM (Figure 3a). Surprisingly, despite the weak expression of TRPV1, both HPFs and CAFs are
more sensitive to CBD than WIN 55-212.2 mesylate treatment. This effect could be due to the expression
of other receptors for which CBD binds as a full agonist, such as peroxisome proliferator-activated
receptor (PPAR)-γ and serotonin receptor 5-HT [28]. In contrast, HPFs and CAFs viability is similarly
and poorly affected by WIN 55-212.2 mesylate, underling that CBs do not likely regulate survival
pathways in these stromal cells.
Therefore, we evaluated if cannabinoids treatment could impair CAFs activation and reactivity.
In according to the literature, we choose cannabinoid concentration at 2.5µM to perform functional assay,
since this concentration does not affect cell survival of both cancer cells and fibroblasts. CAFs, as well as
HPFs activated in vitro with TGF-β, were treated with WIN 55-212.2 mesylate and CBD 2.5 µM for 24 h
and then analyzed by a panel of functional assays. Our results show that the treatment of CAFs with
WIN 55-212.2 mesylate reduces α-smooth muscle actin (SMA) and matrix metalloproteinase (MMP)-2
expression (Figure 3b,d) and decreased CAFs invasion abilities (Figure 3e). Similarly, in TGF-β-activated
HPFs, WIN 55-212.2 mesylate 2.5 µM is able to impair TGF-β-activation, preventing the induction of
α-SMA and MMP-2 expression (Figure 3c,d) and invasion abilities (Figure 3f).
Figure 3. Cont.
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Figure 3. WIN 55-212.2 mesylate affects CAFs’ reactivity and impairs TGF-β-mediated activation of
HPFs. (a) HPFs and CAFs were treated with increasing concentrations of WIN 55-212.2 mesylate
and CBD for 24 h; then, cells survival was determined by crystal violet staining. Data represent
means ± SEMs of three independent biological replicates. p-values were determined by Student’s
t test. * p < 0.05, ** p < 0.01, *** p < 0.001 WIN versus control (Untr); ## p < 0.01, ### p < 0.001
CBD versus Untr. We choose cannabinoid concentration at 2.5 µM to perform all functional assay.
(b,c) Western blot analysis and quantitative measurement of α-SMA expression in CAFs (upper) and
HPFs activated in vitro by TGF-β 10 ng/mL (lower) treated with WIN 55-212.2 mesylate and CBD
2.5 µM for 24 h. Data represent means ± SEMs of three independent biological replicates performed
on fibroblasts isolated from two different explants. Relative α-SMA expressions were normalized
respect to GAPDH and represented as FC versus control Untr. p-values were calculated by one-way
ANOVA followed by Bonferroni’s multiple comparison test. * p < 0.05 versus Untr; # p < 0.05 versus
TGF-β. (d) Gelatin zymography of conditioned media (CM) 10 fold concentrated from CAFs (left) and
HPFs (right) treated like above. The white numbers in bolt indicate quantification of two independent
biological replicates. (e,f) 1 × 105 CAFs (left) or HPFs activated in vitro by TGF-β 10 ng/mL (right) were
treated with cannabinoids 2.5 µM and allowed to invade toward complete medium (10% FBS) for 24 h.
Data represent means ± SEMs of three biological replicates. One-way ANOVA, Bonferroni’s corrected.
* p < 0.05, ** p < 0.01 versus Untr; § p < 0.05, §§ p < 0.01 versus WIN; ### p < 0.001 versus TGF-β. (g)
3 × 104 PC-3 cells were incubated with CM from CAFs treated or not with cannabinoids 2.5 µM and
allowed to invade toward complete medium. Starved cells have been used as negative control (Untr).
Results express means ± SEMs of three independent biological replicates performed with CM from two
different CAFs. One-way ANOVA, Dunnet’s corrected. ± p < 0.05 versus CM CAFs.
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We previously demonstrated that CAFs reactivity is crucial to induce an epithelial to mesenchymal
transition (EMT) of PC-3 cells gaining them with pro-invasive capabilities [14,29,30]. Thus, to evaluate
if cannabinoids could affect also the pro-invasive activity of CAFs, PC-3 cells were exposed for 48 h to
the conditioned media obtained from CAFs treated or not with cannabinoids. Our results demonstrate
that WIN 55-212.2 mesylate severely reduces CAFs-induced invasiveness of PC-3 cells (Figure 3g).
The inhibition of tumor cell invasion triggers by CBD is probably due to high expression of TRPV1 in
androgen-insensitive cells.
Finally, to address which CB modulates the effects of WIN 55-212.2 mesylate in ex vivo cultures
of human CAFs, fibroblasts were pre-treated with selective antagonists of CB1 and CB2, AM281 and
JTE-907 respectively, and analyzed for changes in α-SMA and MMP-2 expression. We chose the antagonists
concentration to be 0.5 µM by evaluating ERK1/2 phosphorylation in a dose-response experiment
(Figure S1b). Cell viability following 24 h of incubation with CBs antagonists was also assessed (Figure S1c).
Pre-treatment with JTE-907, followed by the treatment with WIN 55-212.2 mesylate prevented the
downregulation of both the proteins induced by the synthetic cannabinoid, underlining an involvement of
CB2 receptors in mediating CAFs response to WIN 55-212.2 mesylate Figure 4a,b).
Figure 4. The effect of WIN 55-212.2 mesylate on CAFs phenotype is mainly mediated by CB2.
(a) Representative immunoblot of α-SMA expression in CAFs isolated from two different explants
(CAF1/CAF2) treated with WIN 55-212.2 mesylate 2.5 µM for 24 h in presence or not of AM281 and
JTE-907 0.5 µM. Cells were pre-treated for 3 h with the antagonists, then WIN 55-212.2 mesylate was
added. (b) Quantitative results of western blot analysis. Relative expressions were normalized with
respect to GAPDH and shown as FC respect to control cells maintained in serum-deprived medium (Untr).
Data represent means ± SEMs of three independent biological replicates performed on two different
patient-derived CAFs. One-way ANOVA, Bonferroni’ corrected. * p < 0.05 versus Untr; § p < 0.05 versus
WIN. (c) Gelatin zymography of conditioned media (10 fold concentrated) from CAFs treated as above.
The white numbers in bolt indicate quantification of two independent biological replicates.
Int. J. Mol. Sci. 2020, 21, 787 8 of 16
2.4. The Endocannabinoids Self-Sustain the Migration of Androgen-Insensitive Prostate Cancer Cells and
CAFs’ Reactivity by an Autocrine Loop
Several studies have already described the anti-proliferative effects of exogenous administrated
endocannabinoids in prostate cancer cells [6–12]. The two primary endocannabinoids are
N-arachidonoylethanolamine (anandamide, AEA), which binds CB1 with high affinity, but it is unable to
activate CB2, and 2-arachydonoyl glycerol (2-AG), which acts as full agonist for both CBs [31,32]. It has
been proven that AEA inhibits cell proliferation either in androgen-sensitive or insensitive prostate cancer
cell lines via CB1 [9,10,33]. Furthermore, both AEA and 2-AG have been shown able to induce apoptosis
both in tumor cell lines and in primary cultures of prostate cancer cells [7]. However, the contribution
of an autocrine loop of endocannabinoids in modulating cancer aggressiveness it has been described
only in a very few studies. Nithipatikom et al. showed that LNCaP, PC-3, and DU-145 produce 2-AG at
high concentrations. In addition, these authors reported that the increase of endogenous 2-AG, induced
by blocking its metabolism, inhibits androgen-insensitive prostate cancer cells invasion, while LNCaP
invasiveness is unaffected [33]. Accordingly, we decided to investigate how the blocking of CB1 and CB2
with AM281 and JTE-907 could impair PC-3, and DU-145 cells migration. Tumor cells were treated with
different concentrations of CBs antagonists, administrated alone or in combination. As a control, we used
cells maintained in serum-deprived medium (Untr). Our results show that in androgen-insensitive cell
lines, a lower dose of AM281 (0.5 µM) significantly reduces tumor cell migration, while the concentration
of 1 µM restores the number of migrating cells at the same level of the control (Untr), in both PC-3 and
DU-145 cells (Figure 5a,b). On the contrary, CB2 antagonist JTE-907 does not elicit different response at
the different tested doses, showing a better inhibitory outcome at 1 µM. The response to the treatment
in terms of cancer cell survival has been also shown to exclude toxic effects (Figure S1d). Based on these
results, we therefore evaluated if CAFs’ reactivity could also be regulated by an autocrine self-sustaining
loop of endocannabinoids. Our results show that CB2 impairment by JTE 1 µM (administrated alone or
in combination with AM281), strongly reduces α-SMA expression (Figure 5c), suggesting a role of the
endocannabinoids-mediated signalling in maintaining the CAFs active phenotype.
Figure 5. Cont.
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Figure 5. The endocannabinoids affect the migration abilities of androgen-insensitive prostate cancer
cells and CAFs’ reactivity by autocrine self-sustaining loops. (a,b) 3 × 104 PC-3 (left) or DU-145 (right)
cells were pre-treated for 24 h with different concentrations of AM281 and JTE-907 administrated
alone or in combination. Tumor cells were allowed to migrate for 16 h towards complete medium
(10% FBS). Cells maintained in serum-deprived medium were used as controls (Untr). Data represent
means ± SEMs of three independent biological replicates. *** p < 0.001 versus Untr. (c) Representative
immunoblot of α-SMA expression on CAFs treated with different concentrations of CBs antagonists,
administrated alone or in combination, for 24 h.
3. Discussion
To date, an increasing number of preclinical studies have reported exciting anticancer properties of
cannabinoid-related drugs, both in vitro and in xenograft models of several human cancers, including
prostate cancer [1–13]. Interestingly, cannabinoids have been shown to selectively target tumor cells,
which upregulate CBs compared with their healthy counterparts. Furthermore, in non-transformed cells
that constitutively express CB1 and CB2, cannabinoids modulate cell-survival and cell-death pathways
differently than in tumor cells. The best-established example is that of glioma cells and astrocytes.
In glioma cells, CB1 activation induces de novo ceramide synthesis, which correlates with inhibition
of Akt survival pathway and cell death [34–36]. On the contrary, in astrocytes CB1-mediated pathway
is associated with Akt phosphorylation and cell survival [37,38]. This differential response has been
reported also in rat thyroid epithelial cell lines and skin carcinoma cells [39,40]. Our data now reinforce
this outcome selectivity of cannabinoids, showing that WIN 55-212.2 mesylate at concentrations higher
than 5 µM induces cell death in prostate cancer cell lines, both androgen-sensitive and insensitive,
without affecting healthy prostate epithelial cells (Figure 1a). Similarly, CBD 5 µM triggers cell death in
cancer cell lines, while PNT-1 viability is not affected. It is not surprising that in response to cannabinoids’
concentration being higher than 30 µM, cell survival tends to increase in both healthy and cancer cells.
Indeed, several studies have demonstrated that doses and the duration of the treatment are determinant
factors to induce anti-neoplastic or pro-tumoral activity, which also depends on the agonist administered
and the type of tumor [41–44]. This effect might rely, at least in part, on cannabinoids’ capacity to form
homo- or hetero-oligomers in response to various agonists, interfering with the activation of other G
signaling proteins different from inhibitory G proteins normally coupled to CB1 and CB2 [3,45]. However,
the molecular basis of this “yin and yang” behavior remain an open question in cannabinoid field.
Since TME is now recognized as a hallmark of cancer, and stromal cells coevolve with tumor cells
and sustain tumor progression [46], assessing the effect of cannabinoids on the microenvironmental
components is of exciting interest. Here, we showed for the first time that patient-derived CAFs upregulate
CBs compared to HPFs isolated from the healthy region (Figure 2a,b). This result is consistent with the
increased expression of CB1 and CB2 in HPFs in response to tumor-secreted inflammatory cytokines
(Figure 2c–e). In particular, HPFs and CAFs exhibit a different expression profile of CBs: CB2 expression
is more than 2-fold higher in CAFs than in HPFs, CB1 is upregulated in CAFs, although to lesser
Int. J. Mol. Sci. 2020, 21, 787 10 of 16
extent, and TRPV1 is weakly expressed in both cell types. However, the treatment with WIN 55-212.2
mesylate does not affect cell survival, while CBD strongly impairs fibroblast viability (Figure 3a). These
results suggest that CBD-mediated cell death could be dependent on signalling from non-canonical CBs,
such as PPAR-γ. In keeping with that theme, Ramer et al. recently demonstrated that CBD induces
apoptosis in primary cultures and cell lines of lung carcinoma via cyclooxygenase 2 and PPAR-γ [47].
Fibroblasts’ response to WIN 55-212.2 mesylate is supported by several studies reporting that the effect
of THC and its analogues on cell survival is mediated by CB1, while CB2 regulates its anti-inflammatory
properties [9,48–51]. We proved that treatment with WIN 55-212.2 mesylate strongly affects the CAFs’
phenotype and their ability to increase tumor cell invasiveness, via the CB2 receptor (Figures 3b–g and 4).
The controversial effect of CBD on activated stromal cells invasion should be further investigated to
clarify its role on the modulation of stromal reactivity and the expression of other CBD sensitive receptors,
and the role of CBD as an inverse agonist/antagonist should be evaluated. Our results are supported by
previous studies demonstrating that cannabinoids are able to reduce inflammation and modulate wound
healing processes in mouse models of autoimmune disorders [52]. If we consider cancer as a state of
chronic inflammation, our data strongly reinforce the use of cannabinoids as a next generation treatment
for cancer.
Finally, it has been widely demonstrated that alterations in endocannabinoid system correlate with
tumor onset and progression [1,2,21,22,53]. Then, we wondered whether in addition to the inhibitory effect
triggered by targeting CB1 and CB2 with synthetic agonists, the blocking of endogenous system could affect
cancer and stromal reactivity. Our results suggest that both migration abilities of androgen-insensitive
prostate cancer cells and prostate CAFs reactivity could be in part sustained by an autocrine self-sustaining
loop of endocannabinoids (Figure 5). Interestingly, the involvement of CB2 has been demonstrated in tumor
and stromal cells, as observed by the decrease of both cancer cell migration and CAFs α-SMA expression
following the treatment with the selective antagonist JTE-907. In contrast, the treatment with AM281,
the selective antagonist of CB1, showed, in tumor cells, opposite effects at 0.5 and 1 µM, suggesting that the
biological effects of CB1 impairment could be dependent on the concentration and cell type, as already
reported in the literature. Indeed, Endsley et al. showed that 2-AG may exert anti- and pro-invasive
properties on prostate cancer cells depending on concentration [10,12]. They showed that autocrine 2-AG
exhibited an anti-invasive effect in androgen-independent prostate cancer cells [10]. In contrast, when
2-AG was exogenously added at 1 µM, PC-3 and DU-145 cells invasiveness significantly increased [12].
Accordingly, both endogenous CB1 and CB2 agonists and antagonists may exert different effects depending
on the concentration. Further studies will be needed to clarify this response.
Overall, our results stress the importance of the endocannabinoid system in prostate cancer
progression and reinforce the therapeutic potential of WIN 55-212.2 mesylate in prostate cancer
treatment, since it is able to simultaneously impact on cancer cells and stromal compartments. Further
studies will be needed to clarify the role of endocannabinoids in tumor progression and aggressiveness
in order to develop new possible therapeutic approaches to counteract tumor progression.
4. Materials and Methods
4.1. Antibodies and Reagents
For the western blot analysis, the following antibodies were used: anti- α -SMA (#number
A5228) from Sigma-Aldrich (Darmstadt, Germany); anti-CB1 (#number ACR-001) and anti-TRPV1
(#number ACC-030) from Alomone Labs (Jerusalem BioPark (JBP), Jerusalem, Israel); anti-CB2
(#number sc-293188), anti-GAPDH (#number sc-365062), and secondary antibodies from Santa Cruz
Biotechnology (Dallas, TX, USA); anti-ERK1/2 (#number 9102), pERK1/2 (#number 9101), SMAD2/3
(#number D7G7) and pSMAD2/3 (#number D27F4) from Cell signaling (Danvers, MA, USA). All primary
antibodies, except for anti-CB1 (1:500), were used at 1:1000. CBD (#number 90899) was purchased from
Sigma-Aldrich (Darmstadt, Germany), and WIN 55-212.2 mesylate (#1038) was from Tocris Bioscience
(prior Ministerial Decree SP/096, released on September 11th 2018) (Bristol, UK). Recombinant TGF-β 1
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(#number 130-095-067) was provided from Miltenyi Biotec (Bergisch Gladbach, Germany), human
TNF-α (#number 300-01A) and IL-6 (#number GMP200-06) were from PeproTech (London, UK). TGF-
β receptor inhibitor (A8301, #number 2939), and CB1 and CB2 antagonists (AM281, #number 1115 and
JTE-907, #number 2479, respectively), were from Tocris Bioscience (Bristol, UK). Blocking antibodies for
IL-6 (α-IL-6, #number mabg-hil6-3) were from InvivoGen (San Diego, CA, USA). Matrigel™, Basement
Membrane Matrix (#number 356234) was from BD Biosciences (Allschwil, Swiss).
4.2. Cell Models and Cell Cultures
LNCaP and PNT-1 cells were purchased from Sigma-Aldrich (Darmstadt, Germany); PC-3 and
DU-145 cells were from the American Type Culture Collection (ATCC, Manassas, VA, USA). PC-3
cells were grown in HAM’S F12 medium; DU-145 cells were cultured in DMEM, LNCaP and PNT-1
cells were cultured in RPMI 1640. Human prostate fibroblasts were isolated from aggressive prostate
cancer-bearing patients (Gleason score 4+5, 4+4, grade ≤ pT3), with HPFs and CAFs deriving from the
healthy region and the intra-tumoral area, respectively. The isolated HPFs and CAFs were maintained
in DMEM. The patients enrolled in the study underwent prostatectomy without receiving prior
hormone deprivation therapy. All the enrolled patients provided their signed informed consent,
in agreement with the Ethics Committee of the Azienda Ospedaliera Universitaria Careggi (approval
code: CEAVC – 2018-256, on October 10th 2018). All the cells used were grown at 37 ◦C/5% CO2.
All cultured media were purchased from EuroClone (Milano, Italy) and supplemented with 10%
fetal bovin serum (FBS, EuroClone, Milano, Italy), 1% penicillin/streptomycin and 2 mM glutamine
(Sigma-Aldrich, Darmstadt, Germany).
4.3. Conditioned Media Preparation
Conditioned media were obtained from sub-confluent cells maintained in serum-free medium
(St Med) for 48 h. Once collected, conditioned media were filtered and used freshly or frozen at −80 ◦C
until use.
4.4. Western Blot Analysis
Cells were lysed in Ripa buffer (Thermo Fisher, Waltham, MA, USA), after the addition of
protease and phosphatase inhibitor cocktails (#number P1860 and #number 026M4058V, Sigma-Aldrich,
Darmstadt, Germany), and total proteins were quantified with BCA assay (#number SLCC1765,
Sigma-Aldrich, Darmstadt, Germany). Between 10 and20 µg of total protein lysate was loaded on each
precast gel (4–20% acrylamide, mini-PROTEAN TGX Stain-Free, Bio-Rad, Hercules, CA, USA), and
that was transferred onto a membrane by the Trans-Blot Turbo Transfer System (Bio-Rad, Hercules, CA,
USA). The immunoblot was performed as previously described [14] and was analyzed by Amersham
Imager 600 (GE, Healthcare Life Sciences, Marlborough, MA, USA).
4.5. Crystal Violet Staining
HPFs and CAFs (3 × 104 cells) or prostate cancer cells (1 × 104 cells) were seeded in 24-multiwell
plates and maintained in St Med for 24 h, before receiving WIN 55-212.2 mesylate or CBD,
at concentrations ranging from 0.5 to 100 µM. After 24 h, cells were washed twice with PBS, fixed with
formaldehyde 4% (v/v), and then incubated at room temperature with crystal violet solution (crystal
violet 0.5% (w/v) and methanol 20% (v/v)). After the incubation, the cells were washed with PBS and
treated with SDS 2% (w/v) for 1 h at 37 ◦C. The absorbance at 595 nm was measured.
4.6. Gelatin Zymography
Conditioned media from CAFs and HPFs activated in vitro by TGF- β 10 ng/mL, treated or
not for 24 h with cannabinoids (WIN 55-212.2 mesylate and CBD 2.5 µM) and CBs antagonists
(AM281 and JTE-907 0.5 µM), were collected, 10-fold concentrated with Amicon centrifugal filter
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(UFC800324, Merck-Millipore, Burlington, MA, USA) and analyzed by gelatin zymography as
previously described [54].
4.7. Boyden Chamber Assay
Invasion and migration assays were performed in transwells (8 µm pore polyvinylpyrrolidone-free
polycarbonate filters, #number CC3422, Corning, Corning, NY, USA) with or without pre-coating with
50 µg/cm2 of reconstituted Matrigel, as previously described [27]. Briefly, CAFs and HPFs activated
in vitro by TGF- β 10 ng/mL, were serum-starved for 24 h and then treated with WIN 55-212.2 mesylate
and CBD 2.5 µM for an additional 24 h. Then, 1 × 105 fibroblasts were added to the upper chamber
of Matrigel-coated transwells and allowed to invade at 37 ◦C for 24 h towards complete medium
(20% FBS).
PC-3 cells were incubated at 37 ◦C for 48 h with conditioned media from CAFs treated or not
with WIN 55-21.2 mesylate and CBD 2.5 µM. Then, 3 × 104 cells were added to the upper chamber
of Matrigel-coated transwells and allowed to invade at 37 ◦C for 16 h towards complete medium
(10% FBS).
To investigate the effect of an endocannabinoids autocrine self-sustaining loop on cell migration,
PC-3 or DU-145 cells were treated at 37 ◦C for 24 h with AM281 and JTE-907 at 0.5 µM and 1 µM.
The pharmacological agents were administrated alone or in combination and added again during the
migration assay. 3 × 104 PC-3 and DU-145 cells were allowed to migrate in transwells at 37 ◦C for 16 h
towards complete medium (10% FBS).
The migration/invasion was reported as fold change (FC) compared with the starved control (Untr).
4.8. Statistical Analysis
Statistics were performed using Prism 8 (GraphPad Software, San Diego, CA, USA). Data were
represented as the means ± SEM of at least three independent experiments. Statistical analysis was
performed by Student’s t test or one-way analysis of variance (ANOVA) followed by post-hoc test.
The significance was set at p value < 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/3/787/s1.
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CB1 Cannabinoid receptor 1
CB2 Cannabinoid receptor 2
CBD Cannabidiol
EMT Epithelial to mesenchymal transition
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IL-6 Interleukin-6
MMP-2 Matrix metalloproteinase-2
PPAR-γ Peroxisome proliferator-activated receptor gamma
TGF-β Transforming growth factor beta
THC Delta-9-tetrahydrocannabinol
TME Tumor microenvironment
TNF-α Tumor necrosis factor alpha
TRPV1 Vanilloid receptor 1
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